Second-Line Bedaquiline-Based Regimens Demonstrates Microbiological Response in Patients With TB
March 4th 2024The regimen, which was used as second-line treatment in patients with drug-resistant TB, had a similar microbiological response to those with drug-sensitive TB taking first-line regimens.
Read More
FDA Accepts Priority Review for Linvoseltamab to Treat Adult Patients With R/R MM
February 22nd 2024Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.
Read More
FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
February 16th 2024This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.
Read More